Opiant Pharmaceuticals, Inc. – NASDAQ:OPNT
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Opiant Pharmaceuticals stock price monthly change
+3.10%
month
Opiant Pharmaceuticals stock price quarterly change
+2.28%
quarter
Opiant Pharmaceuticals stock price yearly change
-28.79%
year
Opiant Pharmaceuticals key metrics
Market Cap | 108.79M |
Enterprise value | 87.24M |
P/E | -3.16 |
EV/Sales | 4.96 |
EV/EBITDA | -2.84 |
Price/Sales | 6.04 |
Price/Book | 5.17 |
PEG ratio | -0.01 |
EPS | -6.58 |
Revenue | 191.42M |
EBITDA | -30.66M |
Income | -33.48M |
Revenue Q/Q | 1138.33% |
Revenue Y/Y | 431.25% |
Profit margin | -188.48% |
Oper. margin | -179.48% |
Gross margin | 77.99% |
EBIT margin | -179.48% |
EBITDA margin | -16.02% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOpiant Pharmaceuticals stock price history
Opiant Pharmaceuticals stock forecast
Opiant Pharmaceuticals financial statements
| Dec 2021 | 13.03M | 752.33K | 5.77% |
|---|---|---|---|
| Mar 2022 | 2.19M | -12.58M | -573.94% |
| Jun 2022 | 2.32M | -11.73M | -504.52% |
| Sep 2022 | 173.87M | -9.91M | -5.7% |
| 2022-05-10 | -0.91 | -2.43 |
|---|---|---|
| 2022-08-11 | -1.36 | -2.31 |
| 2022-11-14 | -1.49 | -1.92 |
| Dec 2021 | 70427798 | 23.58M | 33.49% |
|---|---|---|---|
| Mar 2022 | 60318818 | 21.05M | 34.91% |
| Jun 2022 | 48824444 | 19.22M | 39.38% |
| Sep 2022 | 41950149 | 21.44M | 51.13% |
| Dec 2021 | 2.00M | 30K | 556.88K |
|---|---|---|---|
| Mar 2022 | -2.10M | 12.51M | 97.45K |
| Jun 2022 | -10.62M | 2.49M | 135.67K |
| Sep 2022 | -4.74M | -411.08K | 402.61K |
Opiant Pharmaceuticals alternative data
| Aug 2023 | 37 |
|---|---|
| Sep 2023 | 37 |
| Oct 2023 | 37 |
| Nov 2023 | 37 |
| Dec 2023 | 37 |
| Jan 2024 | 37 |
| Feb 2024 | 37 |
| Mar 2024 | 37 |
| Apr 2024 | 37 |
| May 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
Opiant Pharmaceuticals other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 36339 | 0 |
| Jun 2022 | 5700 | 45657 |
| Jul 2022 | 0 | 5427 |
| Jan 2023 | 0 | 17038 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CRYSTAL ROGER director, 10 perc.. | Common Stock | 1,358 | $20.26 | $27,513 | ||
Sale | O'TOOLE DAVID D officer: Chief Fi.. | Common Stock | 541 | $20.26 | $10,961 | ||
Sale | GORMAN BRIAN other: General Counsel | Common Stock | 444 | $20.26 | $8,995 | ||
Sale | ELLISON MARK JASON HEATH officer: Chief Development Offi.. | Common Stock | 610 | $20.26 | $12,359 | ||
Sale | SKOLNICK PHIL officer: Chief Scientific Officer | Common Stock | 480 | $20.26 | $9,725 | ||
Sale | O'TOOLE DAVID D officer: Chief Fi.. | Common Stock | 415 | $20.2 | $8,383 | ||
Sale | ELLISON MARK JASON HEATH officer: Chief Development Offi.. | Common Stock | 469 | $20.2 | $9,474 | ||
Sale | SKOLNICK PHIL officer: Chief Scientific Officer | Common Stock | 369 | $20.2 | $7,454 | ||
Sale | CRYSTAL ROGER director, 10 perc.. | Common Stock | 1,183 | $20.2 | $23,897 | ||
Sale | ELLISON MARK JASON HEATH officer: Chief Development Offi.. | Common Stock | 1,806 | $20.2 | $36,481 |
| Patent |
|---|
Application Filling date: 17 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 7 Nov 2019 Issue date: 30 Dec 2021 |
Application Filling date: 13 May 2021 Issue date: 9 Sep 2021 |
Application Filling date: 18 Dec 2020 Issue date: 9 Sep 2021 |
Application Filling date: 15 May 2019 Issue date: 22 Jul 2021 |
Application Filling date: 7 May 2020 Issue date: 1 Apr 2021 |
Application COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST Filling date: 17 Jun 2020 Issue date: 21 Jan 2021 |
Application COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST Filling date: 17 Jun 2020 Issue date: 24 Dec 2020 |
Application Filling date: 19 Dec 2019 Issue date: 17 Dec 2020 |
Application COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST Filling date: 5 Dec 2019 Issue date: 11 Jun 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2022 12 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 14 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 15 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 11 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Roger Crystal (1976) Pres, Chief Executive Officer & Director | $920,580 |
Dr. Phil Skolnick D.Sc. (hon), Ph.D. (1947) Chief Scientific Officer | $685,780 |
| Mr. David D. O'Toole (1959) Chief Financial Officer | $618,950 |
-
When is Opiant Pharmaceuticals's next earnings date?
Unfortunately, Opiant Pharmaceuticals's (OPNT) next earnings date is currently unknown.
-
Does Opiant Pharmaceuticals pay dividends?
No, Opiant Pharmaceuticals does not pay dividends.
-
How much money does Opiant Pharmaceuticals make?
Opiant Pharmaceuticals has a market capitalization of 108.79M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 48.62% to 40.73M US dollars. Opiant Pharmaceuticals earned 3.01M US dollars in net income (profit) last year or -$1.92 on an earnings per share basis.
-
What is Opiant Pharmaceuticals's stock symbol?
Opiant Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "OPNT".
-
What is Opiant Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Opiant Pharmaceuticals?
Shares of Opiant Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Opiant Pharmaceuticals's key executives?
Opiant Pharmaceuticals's management team includes the following people:
- Dr. Roger Crystal Pres, Chief Executive Officer & Director(age: 49, pay: $920,580)
- Dr. Phil Skolnick D.Sc. (hon), Ph.D. Chief Scientific Officer(age: 78, pay: $685,780)
- Mr. David D. O'Toole Chief Financial Officer(age: 66, pay: $618,950)
-
How many employees does Opiant Pharmaceuticals have?
As Jul 2024, Opiant Pharmaceuticals employs 37 workers.
-
When Opiant Pharmaceuticals went public?
Opiant Pharmaceuticals, Inc. is publicly traded company for more then 18 years since IPO on 4 Jun 2007.
-
What is Opiant Pharmaceuticals's official website?
The official website for Opiant Pharmaceuticals is opiant.com.
-
Where are Opiant Pharmaceuticals's headquarters?
Opiant Pharmaceuticals is headquartered at 233 Wilshirre Boulevard, Santa Monica, CA.
-
How can i contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals's mailing address is 233 Wilshirre Boulevard, Santa Monica, CA and company can be reached via phone at +31 5985410.
Opiant Pharmaceuticals company profile:
Opiant Pharmaceuticals, Inc.
opiant.comExchange:
NASDAQ
Full time employees:
37
Industry:
Biotechnology
Sector:
Healthcare
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
233 Wilshirre Boulevard
Santa Monica, CA 90401
Santa Monica, CA 90401
CIK: 0001385508
ISIN: US6837501039
CUSIP: 683750103
